Proliferative diabetic retinopathy treated with intravitreal ranibizumab and photocoagulation directed at ischemic retinal areas—A randomized study
Authors:
- 4 August 2021
- journal article
- research article
- Published by Springer Nature in Documenta Ophthalmologica
- Vol. 143 (3) , 313-322
Abstract
Purpose To compare ETDRS panretinal laser photocoagulation (PRP) combined with intravitreal injection of ranibizumab (IVR) and photocoagulation targeted to ischemic retina (PIR) combined with IVR in patients with proliferative diabetic retinopathy (PDR). Methods PDR patients were randomly assigned to treatment with either PRP + IVR or PIR + IVR. ETRDS Best-corrected visual acuity (BCVA) and central subfield thickness (CSFT) measured on optic-coherence tomography images (OCT-Heidelberg Spectralis) were recorded at baseline and every 4 weeks for one year. Fluorescein leakage area (FLA) from active new vessels was measured every 12 weeks. Full-field ERG was recorded by means of DTL electrodes, following ISCEV standard recommendations, at baseline and after 3 months. Results Twenty-eight eyes completed the study period. At baseline, mean ± SE BCVA (logMAR) was 0.44 ± 0.07 and 0.37 ± 0.08 (P = 0.5030); CSFT (μm) was 324.0 ± 20.4 and 330.1 ± 22.1 (P = 0.8417); and FLA (mm2) was 16.10 ± 4.42 and 9.97 ± 1.83 (P = 0.2114) for PRP + IVR and PIR + IVR groups, respectively. There were no relevant changes on BCVA or CSFT, but a significant reduction for FLA was observed at all visits compared to baseline for both groups, with no differences between groups. ERG showed at baseline reduced dark-adapted amplitudes, and these changes were also significantly amplified after laser treatment. ROD b-wave amplitude was further reduced in 62 ± 6% for PRP + IVR and 59 ± 4% for group PIR + IVR, but with no between-groups significant difference (P = 0.9082). Conclusions PIR + IVR or PRP + IVR are comparable strategies regarding FLA control in PDR and led to similar retinal function impairment, based on ERG changes up to one-year follow-up. Trial registration number NCT03904056, date of registration 02/11/2019, retrospectively registered.Keywords
Funding Information
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2012/16265-0, and 2013/02169-2)
This publication has 18 references indexed in Scilit:
- Electroretinographic findings associated with panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab treatment for high-risk proliferative diabetic retinopathyDocumenta Ophthalmologica, 2012
- Diabetic RetinopathyNew England Journal of Medicine, 2012
- Optos‐guided pattern scan laser (Pascal)‐targeted retinal photocoagulation in proliferative diabetic retinopathyActa Ophthalmologica, 2011
- Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathyActa Ophthalmologica, 2011
- Ranibizumab for Retinal NeovascularizationOphthalmology, 2011
- Ultra Wide Field Fluorescein Angiography Guided Targeted Retinal Photocoagulation (TRP)Seminars in Ophthalmology, 2009
- INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR PERSISTENT NEW VESSELS IN DIABETIC RETINOPATHY (IBEPE STUDY)Retina, 2006
- Role of vascular permeability factor/vascular endothelial growth factor in eye diseaseBritish Journal of Ophthalmology, 1997
- Visual Impairment and Retinopathy in People With Normal Glucose Tolerance, Impaired Glucose Tolerance, and Newly Diagnosed NIDDMDiabetes Care, 1991
- Retinal function of the diabetic retina after argon laser photocoagulation assessed electroretinographically.British Journal of Ophthalmology, 1985